REGISTRY participants (n=1993) | |
---|---|
Sociodemographics | |
Sex, male | 1019 (51.1) |
Age, years | 50.3±12.3 |
Clinical characteristics | |
CAG repeat length, number | 44.6±4.3 |
Duration of disease, years* | 5.9 (3.4–9.9) |
TMS, points | 35.3±19.8 |
TFC, points | 8 (5–12) |
Disease stage | |
Stage 1 | 662 (33.2) |
Stage 2 | 655 (32.9) |
Stage 3 | 513 (25.7) |
Stage 4 | 140 (7.0) |
Stage 5 | 23 (1.2) |
Psychotropic medication use | |
Any psychotropics† | 1117 (56.0) |
Benzodiazepines‡ | 338 (17.0) |
Antidepressants§ | 692 (34.7) |
Antipsychotics¶ | 679 (34.1) |
Mood stabilisers/antiepileptics** | 144 (7.2) |
Behavioural subscale scores | |
Depression, points | 3 (0–10) |
Irritability/aggression, points | 1 (0–5) |
OCBs, points | 0 (0–3) |
Apathy, points | 1 (0–6) |
Psychosis, points | 0 (0–0) |
Data are presented as n (%), mean (±SD) or median (IQR) when appropriate.
*Duration of disease is calculated by date of visit minus the rater-estimated date of disease onset.
†111 missings.
‡78 missings.
§85 missing.
¶69 missings.
**19 missings due to missing values for use of psychotropics.
HD, Huntington's disease; OCBs, obsessive/compulsive behaviours; TFC, Total Functional Capacity; TMS, Total Motor Score.